Announcements Trials
Browse Landscape

Status

Recruiting 11Unknown 6Completed 6Terminated 2Not yet recruiting 2

Sponsor Class

INDUSTRY 5OTHER 1

Study Type

Interventional 9Observational 6

Sponsor

Cancer Type

Breast 6

Conditions

Breast Neoplasms 1388Neoplasms 1168Colorectal Neoplasms 626Lung Neoplasms 562Prostatic Neoplasms 538Carcinoma, Non-Small-Cell Lung 444Carcinoma, Hepatocellular 296Stomach Neoplasms 272Pancreatic Neoplasms 270Colonic Neoplasms 264Ovarian Neoplasms 231Head and Neck Neoplasms 228Rectal Neoplasms 221Melanoma 216Multiple Myeloma 204Uterine Cervical Neoplasms 198Lymphoma 195Leukemia 193Precursor Cell Lymphoblastic Leukemia-Lymphoma 191Neoplasm Metastasis 178Carcinoma, Renal Cell 177Brain Neoplasms 174Esophageal Neoplasms 173Leukemia, Myeloid, Acute 158Urinary Bladder Neoplasms 138Recurrence 123Polycystic Ovary Syndrome 122Liver Neoplasms 119Hematologic Neoplasms 117Endometrial Neoplasms 107

Interventions

tucatinib 1trastuzumab deruxtecan 1pyrotinib 1Hospital Information Systems 1Electronic Health Records 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Completed × Observational × HER2-positive Breast Cancer × Clear all
NCT05253911 2025-12-04

TRACE

iOMEDICO AG

Completed
49 enrolled
Breast

HER2-positive Breast Cancer

NCT06833268 2025-07-08

Real-world Outcomes of Patients With HER2+ Metastatic Breast Cancer After Treatment With Trastuzumab Deruxtecan

Daiichi Sankyo

Completed
228 enrolled
Breast

HER2-positive Breast Cancer

NCT05149014 2024-09-26

Safety, Effectiveness and Quality of Life of Trastuzumab Deruxtecan in Patients with HER2+ Breast Cancer

Daiichi Sankyo France

Completed
306 enrolled
Breast

HER2-positive Breast Cancer

NCT05458401 2024-03-15

EUROPA T-DXd

Daiichi Sankyo

Completed
256 enrolled
Breast

HER2-positive Breast Cancer

NCT05769751 2023-08-16

A Study to Describe the Real-world Treatment Patterns and Associated Outcomes in Patients of China With HER2-positive Unresectable or Metastatic Breast Cancer

Daiichi Sankyo

Completed
865 enrolled
Breast

HER2-positive Breast Cancer

NCT04756921 2021-02-16

18F-FDG Uptake Heterogeneity Predicts Pyrotinib Response

Fudan University

Completed
30 enrolled
Breast

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡